Initiate EOS-448 and pembrolizumab trial in solid tumors
Delivered after the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- September 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiation mid-2021”
What we found
Evidence strength A What the grades mean
The company initiated the Phase 1/2 clinical trial of EOS-448 in combination with pembrolizumab in September 2021, which is after the mid-2021 deadline.
-
A iTeos Therapeutics, Inc. 10-Q filed 2021-11-10
“In September 2021, we dosed the first patients in a Phase 1/2 clinical trial of EOS-448 in combination with pembrolizumab and with inupadenant in patients with solid tumors.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- EOS-448 and pembrolizumab trial initiation
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Regulatory, Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you iTeos Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C808865-021560 · Corrections policy